Efficacy and safety of dolutegravir/rilpivirine in real-world clinical practice. GeSIDA study 1119.

R Palacios, C Gómez-Ayerbe, J L Casado, F Tejerina, M L Montes, M Castaño, A Ocampo, D Rial, E Ribera,M J Galindo, C Hidalgo, C Fariñas,M Montero, T Payeras, F Fanjul,J de la Torre,J Santos

HIV medicine（2023）

引用 0|浏览3

暂无评分

摘要

This study confirms the effectiveness, tolerability and safety of DTG/RPV in real-world clinical practice in a different population from clinical trials, with many years of infection, low CD4 nadir, several previous treatment lines, more than half with virological failures, and one-third diagnosed with AIDS. The switch to DTG/RPV was safe with few discontinuations due to adverse effects. Modifications of the lipid and liver profiles were favourable. There were no relevant changes in kidney function.

查看译文

关键词

DTG/RPV,dolutegravir,real-world,rilpivirine

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要